Unknown PHASE2 INTERVENTIONAL 2-arm NCT01669707

Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Beijing Chest Hospital

Interventions Endostar -Continued Pumping into+GP Endostar -injecting into +GP

Updated 8 times since 2017 Last updated: Sep 4, 2018 Started: Apr 30, 2011 Primary completion: Sep 30, 2020 Completion: Sep 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently ongoing. Beijing Chest Hospital leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Oct 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Oct 2018 — Oct 2020 [monthly]

Recruiting PHASE2

Status: Unknown Status → Recruiting

▶ Show 3 earlier versions

Jun 2018 — Oct 2018 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Chest Hospital

Data source: Beijing Chest Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China